1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,890 | 2,140 | 20:16 | |
| 1,990 | 2,020 | 20:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Aclarion, Inc.: Aclarion Announces Nociscan Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology | 1 | GlobeNewswire (USA) | ||
| 29.07. | Aclarion: Scan-Volumen im ersten Halbjahr 2026 um 141 % gestiegen | 3 | Investing.com Deutsch | ||
| 29.07. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 | 468 | GlobeNewswire (Europe) | 141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA... ► Artikel lesen | |
| 09.07. | Aclarion, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.07. | Aclarion adds Texas Spine Care Center to CLARITY trial | 1 | Investing.com | ||
| 07.07. | Aclarion erweitert CLARITY-Studie um Texas Spine Care Center | 2 | Investing.com Deutsch | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 07.07. | Aclarion, Inc.: Aclarion Announces Texas Spine Care Center as New CLARITY Site | 1 | GlobeNewswire (USA) | ||
| 10.06. | Aclarion, Inc.: Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | 2 | GlobeNewswire (USA) | ||
| 09.06. | Aclarion partners with PRIA Healthcare on market access program | 4 | Investing.com | ||
| 09.06. | Aclarion, Inc.: Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | 319 | GlobeNewswire (Europe) | Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK... ► Artikel lesen | |
| 08.06. | Aclarion Comments on Echo Lake News | 1 | Baystreet.ca | ||
| 08.06. | Aclarion, Inc.: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal | 796 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 08.06. | Aclarion, Inc.: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting | 210 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 04.06. | Aclarion, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 03.06. | Aclarion, Inc.: Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation | 2 | GlobeNewswire (USA) | ||
| 01.06. | Aclarion's Nociscan technology used in back pain study | 2 | Investing.com | ||
| 01.06. | Aclarion, Inc.: Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study | 2 | GlobeNewswire (USA) | ||
| 28.05. | Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal | 122 | GlobeNewswire (Europe) | BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... ► Artikel lesen | |
| 28.05. | Echo Lake Capital Offers To Acquire Aclarion Inc. | 316 | ACCESS Newswire | Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse... ► Artikel lesen | |
| 13.05. | Aclarion, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 324,40 | +1,55 % | Intuitive Surgical: Warum UBS jetzt zum Kauf rät | ||
| UNITEDHEALTH | 360,80 | +1,98 % | UnitedHealth (ISIN: US91324P1021): Führend im Gesundheitssektor mit langfristigem Wachstumspotenzial | ||
| THERMO FISHER | 498,10 | +1,74 % | Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings? | ||
| ATOSSA THERAPEUTICS | 2,040 | +0,99 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 58,62 | +5,51 % | Could Centene (CNC) Be Entering a Major Margin Recovery? | ||
| QUIDELORTHO | 15,355 | +0,75 % | QuidelOrtho Corporation: QuidelOrtho Appoints Micah Young as Chief Financial Officer | Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq:... ► Artikel lesen | |
| VERU | 2,330 | -1,69 % | Veru Inc.: Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss | ||
| TEMPEST THERAPEUTICS | 0,925 | +4,26 % | Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T | Tempest's TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage... ► Artikel lesen | |
| NANO-X IMAGING | 1,015 | -5,14 % | Nano-X Imaging Q2 2026 Earnings Preview | ||
| FULGENT GENETICS | 16,200 | +0,62 % | Fulgent expects $330M-$340M 2026 revenue as billing transition lowers collection rates | ||
| LANTHEUS | 87,90 | +0,11 % | XETR US5165441032: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTILLANTHEUS HLDGS DL-... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,606 | +1,09 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results | ||
| OMNICELL | 32,000 | -1,23 % | OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth | ||
| AMN HEALTHCARE SERVICES | 29,000 | 0,00 % | AMN Healthcare Services, Inc.: AMN Healthcare Names New Chief Commercial Officer and Chief People Officer to Advance Growth and Culture | Executive appointments reflect leadership momentum and coordinated investment in growth and people DALLAS, June 15, 2026 /PRNewswire/ -- AMN Healthcare, the leader and innovator in healthcare... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,200 (-9,52 %) liegt der Kurs bei 1,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.